Earnings Releases·Nov 5, 2026, 4:13 PM ET

Adicet Bio — Third Quarter 2026 Earnings Summary

**Financial Results:** Net loss narrowed to $18.9 million ($1.76/share) from $26.9 million ($4.72/share) in the prior year period, driven by a 32% reduction in R&D expenses to $15.6 million and a 17% drop in G&A to $4.2 million; cash and investments decreased to $100.9 million from $158.5 million at year-end 2025.
**Liquidity and Outlook:** Current cash resources are projected to fund operations through the second half of 2027, with management characterizing 2027 as a catalyst-rich year.
**Clinical Milestones:** Prula-cel Phase 1 data showed 50% complete renal response in lupus nephritis patients; a pivotal single-arm study is underway with enrollment expected soon, while regulatory updates and 12-month follow-up data for ~22 patients are anticipated in Q1 2027.
**Pipeline Progress:** The FDA granted Fast Track Designation for ADI-212 in metastatic castration-resistant prostate cancer with Phase 1 startup activities initiated and enrollment expected in Q1 2027; the first in vivo CAR-T candidate is targeted for clinic entry in H2 2027.
**Strategic Initiatives:** The Company plans to engage the FDA in Q4 2026 regarding potential expansion of the pivotal lupus program to include patients without nephritis.